Welcome to Lawsuit.com  

Our mission is to provide each client with the most effective ethical representation possible, and to preserve and promote the civil justice system.

Advisory on Treating IPF with Actimmune

Posted on April 29, 2008

FDA is alerting healthcare professionals that early results of a clinical study have indicated that patients with idiopathic pulmonary fibrosis (IPF) did not show a survival benefit from being treated with Actimmune, a synthetic version of interferon gamma-1b. Actimmune is not approved to treat IPF.

InterMune, the maker of Actimmune, has stopped the study because an interim analysis showed that mortality in IPF patients treated with the drug was 14.5% compared to 12.7% in patients receiving placebo. Reported side effects of treatment included constitutional symptoms, neutropenia, and possibly pneumonia.

Although Actimmune has not been approved to treat IPF, some IPF patients may be receiving this product off-label. Healthcare providers should discuss the results of this trial with IPF patients on Actimmune and should carefully consider whether to continue treatment with the drug.

FDA is evaluating the study results and will notify healthcare providers if the review reveals additional important information.

Additional Information:

FDA MedWatch Safety Alert. Actimmune (Interferon Gamma 1-b). March 12, 2007.
http://www.fda.gov/medwatch/safety/2007/safety07.htm#Actimmune

Lawsuit Membership
Law firms interested in becoming part of this unique legal community should apply here.Join Lawsuit.com

Lawsuit Video Tips
To become a participating member of Lawsuit.com you must supply a video about your firm, talk about the litigation you find important, and how you help your clients. For ideas and video tips on effective videos click here. Video Creation Tips

Become an Editor
Lawsuit.com is currently building one of the largest human-edited legal video databases in the Web 2.0 World. Want to help? Apply here to become an Editor.Comment